Overview
Prilenia is a biopharmaceutical company focused on developing neuroprotective therapies targeting the sigma-1 receptor for neurodegenerative and neuropsychiatric diseases. The company combines drug development expertise with global operations to advance disease-modifying treatments and ensure patient access to innovative neurological therapies.
More in Neurotechnology
Latest industry news
Noninvasive Brain Interface Uses AI Suggestions to Triple Communication Speed
2026-11-21 · Research
Zhongke Borui Closes $15M Round to Scale Brain-Computer Interface Hardware in China
2026-11-20 · Funding
ALS Community Gains a Formal Voice in Brain-Computer Interface Development
2026-11-19 · Policy
Science Corporation Closes $400M Round to Push Brain-Computer Interface Technology Into the Clinic
2026-11-18 · Funding
Company details
Is this your company?
Claim this listing to add your logo, full description, team, and products. Premium listings get featured placement.
Claim & upgrade listingAdvertise
Reach neurotech professionals
Newsletter sponsorships, featured listings, and sponsored articles.
View packages →